Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2011 May;57(1):e1–e6. doi: 10.1097/QAI.0b013e3182158980

Figure 1.

Figure 1

Distribution of ARV drugs within each drug class (adult ART patients). Most patients received a nucleoside reverse transcriptase inhibitor (NRTI) backbone of stavudine (d4T) or zidovudine (AZT) in combination with lamivudine (3TC). Only a small percentage of patients received tenofovir (TNF). Most NRTI backbones were complemented by an nonnucleoside reverse transcriptase inhibitor (NNRTI), with nevirapine (NVP) being the most common. Protease inhibitors (PIs) in resource-limited settings are often reserved for second-line therapy and were used for only a small number of patients.